DELBERT-LABORATORIES
DELBERT Laboratories are proud to announce the acquisition from Noventia Pharma Srl of the European MA of CEPLENE® 0.5mg/0.5ml, solution for injection (histamine dihydrochloride) on September 12, 2022, and strengthens its commitment in hematology-oncology in Europe.
Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study published in Blood in 2006 and received orphan drug designation in 2005 1,2,3.
Acute myeloid leukemias are rare genetic diseases. In Europe, the incidence is estimated at 3.7/100,000 new cases per year. The prognosis for AML is unfavourable with a 5-year relative survival rate of 19%4.
DELBERT Laboratories (https://laboratoires-delbert.fr/) is a French pharmaceutical company specialized in the "renewal of essential medicines" frequently affected by marketing termination, stock shortages, particularly in times of crisis.
"We are focused on keeping essential medicines available to patients in 3 therapeutic areas (Antiinfectives, CNS and Oncology), with the mission of maintaining the therapeutic arsenal of doctors and preventing well-balanced patients from changing treatments.The acquisition of Ceplene's® MA in Europe is part of this strategy to maintain essential medicines and make available medicines with clinical benefit in rare diseases," said Eric Fidelin (Head of Strategy & Global Development).
With this acquisition, DELBERT Laboratories strengthens its presence in hematological oncology.
About DELBERT Laboratories
The mission of DELBERT Laboratories is to maintain access to Drugs of Major Therapeutic Interest for patients. Every year, Delbert Laboratories acquires new drugs whose future is compromised.
DELBERT Laboratories focuses its efforts on finding production sites in Europe. With their collaborators and the support of clinicians, galenicians, engineers and chemists, DELBERT Laboratories are reviving these drugs in order to guarantee their availability to the medical profession and patients.
DELBERT Laboratories will reach more than €30m in turnover in 2022 with double-digit growth each year and already markets 14 products (including 13 originators) with hospital or specialists reserved prescriptions.
DELBERT Laboratories financed this acquisition thanks to trusting relationships with their financial partners who strongly support these values focused on patient access to Drugs of Major Therapeutic Interest.
http://www.laboratoires-delbert.fr/
References:
1. Brune et al., Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood, 1 july 2006 volume 108, number 1, 88-96
2. Nilsson, Malin S., et al. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia. British Journal of Haematology 188.4 (2020): e49
3. Ceplene® Epar, 2008 - EMEA/H/C/000796
4. Visser et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012 Nov;48(17):3257-66.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku opens Rigaku Technology Center Taiwan20.10.2025 17:00:00 CEST | Press release
- Advancing regional growth through engineering and collaboration in Taiwan and beyond - Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a new group company in Taiwan, in 2025. A facility within RTTW, Rigaku Technology Center Taiwan (hereinafter RTC-TW), began full-scale operation in October 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020130286/en/ Rigaku Technology Taiwan Co., Ltd., located in Tai Yuen Hi-Tech Industry Park RTTW will assume duties formerly managed by Rigaku Taiwan Branch (RCTW), established in 2024. As Rigaku’s base of operations in Chinese-speaking East Asia, RTTW aims to strengthen customer support and advance sustainable growth in the region. RTC-TW will serve as an engineering base for advancing R&D, customer support, and joint development. The f
InterSystems and Google Cloud Integrate InterSystems HealthShare with Google Cloud’s Healthcare API20.10.2025 16:00:00 CEST | Press release
Collaboration Strengthens Interoperability and Enables Providers to Harness AI with Reliable Data Foundations InterSystems, a creative data technology provider managing over one billion health records worldwide, today announced a new partnership that integrates InterSystems HealthShare with Google Cloud. Announced at HLTH, this collaboration aims to deliver a scalable, real-time, harmonized data foundation for generative and agentic AI applications. The partnership addresses one of the most pressing challenges in healthcare IT: fragmented and inconsistent data. By combining InterSystems expertise in data harmonization, identity resolution, and interoperability with Google Cloud’s broad suite of AI-enabled analytics and search capabilities and secure infrastructure, healthcare organizations can now unlock the full potential of AI with clean, unified, and actionable data on a proven, enterprise-grade cloud platform. “AI is transforming healthcare, but it can only succeed when it’s ground
Wolters Kluwer supports SOCAR’s digital transformation journey with launch of Enablon Control of Work solution at Pirallahi Island upstream facility20.10.2025 15:30:00 CEST | Press release
Wolters Kluwer today announced that the State Oil Company of the Azerbaijan Republic (SOCAR) has successfully launched the Enablon Control of Work (CoW) solution at its first upstream oil gathering location in the Abşeronneft Oil and Gas Production Department (OGPD), located on Pirallahi Island. In line with its digital transformation efforts, the company shifts from manual, paper-based systems to fully integrated digital workflows for managing work permits, isolations, risk assessments, and safety protocols. As the fully state-owned enterprise responsible for oil and natural gas production from both onshore and offshore fields in the Azerbaijani sector of the Caspian Sea, SOCAR plays a vital role in the nation’s energy infrastructure. It operates Azerbaijan’s only oil refinery, a gas processing plant, and oversees several strategic oil and gas export pipelines. With the rollout of the Enablon CoW solution, SOCAR is strengthening its commitment to standardizing safety practices across
TagEnergy Selects Sitetracker to Accelerate Renewable Energy Growth20.10.2025 15:00:00 CEST | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that TagEnergy, a fast-growing renewable energy producer, has selected Sitetracker to standardize operations and scale its portfolio across multiple markets. The move underscores TagEnergy’s commitment to delivering clean energy projects more efficiently while maintaining the highest standards of quality and transparency. TagEnergy develops and operates wind, solar, and battery storage projects across Europe, Japan and Australia, and is on track to double its size in the next three to four years. To support this growth, the company required a modern, flexible platform to unify processes across departments and countries, eliminate reliance on spreadsheets, and provide real-time visibility into project performance. By deploying Sitetracker, TagEnergy will: Get more done faster by eliminating manual tasks, standardizing workflows, and enabling teams to manage more projects wi
Lenovo Advances the AI-Enabled Workforce with Agentic AI: Trusted, Proven, and Ready to Deliver ROI20.10.2025 15:00:00 CEST | Press release
IDC projects agentic AI to double workforce productivity by 2027, while generative AI is already delivering $4 in return for every $1 invested.Lenovo integrates new agentic AI capabilities across AI PCs, Services, and TruScale DaaS to boost productivity, protection, and enterprise efficiency. As enterprises race to capture value from AI, Lenovo today unveiled new agentic AI capabilities as the centerpiece of its AI-Enabled Workforce portfolio, a complete suite of devices, services, and lifecycle solutions that turn AI investments into measurable business value. According to IDC, enterprises are already realizing nearly $4 in return for every $1 invested in generative AI, and by 2027 agentic AI is expected to double workforce productivity worldwide1 – evidence that organizations are moving from AI experimentation to tangible results. This marks a turning point where enterprises are shifting from piloting AI to embedding intelligent automation across their workforces, and Lenovo is helpi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom